1.Plasma free amino acid profiles of canine mammary gland tumors.
Kazuo AZUMA ; Tomohiro OSAKI ; Takeshi TSUKA ; Tomohiro IMAGAWA ; Saburo MINAMI ; Yoshiharu OKAMOTO
Journal of Veterinary Science 2012;13(4):433-436
The purpose of this study was to elucidate the relationship between plasma free amino acid (PFAA) levels and the clinical stages of mammary gland tumors (MGT) in dogs. PFAA levels in canines with malignant mammary tumors were decreased compared to those of healthy animals. The levels of aspartate and ornithine, in the dogs with tumor metastasis were significantly decreased when compared to those of dogs that did not have metastases. Results of this study indicate that PFAA levels could be a risk factor or biomarker for canine MGT metastasis.
Animals
;
Aspartic Acid
;
Dogs
;
Mammary Glands, Human
;
Neoplasm Metastasis
;
Ornithine
;
Plasma
;
Risk Factors
2.Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma.
Masaki ONOYAMA ; Takeshi TSUKA ; Tomohiro IMAGAWA ; Tomohiro OSAKI ; Saburo MINAMI ; Kazuo AZUMA ; Kazuhiko KAWASHIMA ; Hiroshi ISHI ; Takahiro TAKAYAMA ; Nobuhiko OGAWA ; Yoshiharu OKAMOTO
Journal of Veterinary Science 2014;15(1):117-123
Sixteen cases of malignant soft tissue sarcoma (STS; 10 canines and six felines) were treated with a novel triple therapy that combined photodynamic therapy, hyperthermia using indocyanine green with a broadband light source, and local chemotherapy after surgical tumor resection. This triple therapy was called photodynamic hyperthermal chemotherapy (PHCT). In all cases, the surgical margin was insufficient. In one feline case, PHCT was performed without surgical resection. PHCT was performed over an interval of 1 to 2 weeks and was repeated three to 21 times. No severe side effects, including severe skin burns, necrosis, or skin suture rupture, were observed in any of the animals. No disease recurrence was observed in seven out of 10 (70.0%) dogs and three out of six (50.0%) cats over the follow-up periods ranging from 238 to 1901 days. These results suggest that PHCT decreases the risk of STS recurrence. PHCT should therefore be considered an adjuvant therapy for treating companion animals with STS in veterinary medicine.
Animals
;
Antineoplastic Agents/*therapeutic use
;
Cat Diseases/drug therapy/surgery/*therapy
;
Cats
;
Combined Modality Therapy/veterinary
;
Dog Diseases/drug therapy/surgery/*therapy
;
Dogs
;
Hyperthermia, Induced/veterinary
;
Indocyanine Green/*therapeutic use
;
Photochemotherapy/veterinary
;
Photosensitizing Agents/*therapeutic use
;
Sarcoma/drug therapy/surgery/therapy/*veterinary